PURE Bioscience (PURE) 10-Q 16 Dec 24 2025 Q1 Quarterly report Financial data

Cover

Cover - $ / shares	3 Months Ended
	Oct. 31, 2024	Dec. 16, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--07-31
Entity File Number	001-14468
Entity Registrant Name	PURE Bioscience, Inc.
Entity Central Index Key	0001006028
Entity Tax Identification Number	33-0530289
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	771 Jamacha Rd.
Entity Address, Address Line Two	#512
Entity Address, City or Town	El Cajon
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92019
City Area Code	(619)
Local Phone Number	596-8600
Title of 12(g) Security	Common Stock, $0.01 par value
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		111,856,473
Entity Common Stock, Shares Outstanding	$ 0.01

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Oct. 31, 2024	Jul. 31, 2024
Current assets
Cash and cash equivalents	$ 346,000	$ 349,000
Accounts receivable	371,000	298,000
Inventories, net	72,000	56,000
Restricted cash	75,000	75,000
Prepaid expenses	47,000	27,000
Total current assets	911,000	805,000
Property, plant and equipment, net	13,000	13,000
Total assets	924,000	818,000
Current liabilities
Accounts payable	718,000	601,000
Accrued liabilities	193,000	132,000
Total current liabilities	911,000	733,000
Long-term liabilities
Total long-term liabilities	3,509,000	2,949,000
Total liabilities	4,420,000	3,682,000
Commitments and contingencies
Stockholders’ deficiency
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value: 200,000,000 shares authorized, 111,856,473 shares issued and outstanding at October 31, 2024, and July 31, 2024	1,119,000	1,119,000
Additional paid-in capital	132,669,000	132,612,000
Accumulated deficit	(137,284,000)	(136,595,000)
Total stockholders’ deficiency	(3,496,000)	(2,864,000)
Total liabilities and stockholders’ deficiency	924,000	818,000
Related Party [Member]
Long-term liabilities
Convertible notes payable to related parties	$ 3,509,000	$ 2,949,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2024	Jul. 31, 2024
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	111,856,473	111,856,473
Common stock, shares outstanding	111,856,473	111,856,473

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Total revenue	$ 556,000	$ 722,000
Cost of goods sold	231,000	280,000
Gross Profit	325,000	442,000
Operating costs and expenses
Selling, general and administrative	881,000	1,073,000
Research and development	71,000	80,000
Total operating costs and expenses	952,000	1,153,000
Loss from operations	(627,000)	(711,000)
Other income (expense)
Interest expense to related parties, net	(62,000)	(24,000)
Total other income (expense)	(62,000)	(24,000)
Net loss	$ (689,000)	$ (735,000)
Basic net loss per share	$ (0.01)	$ (0.01)
Diluted net loss per share	$ (0.01)	$ (0.01)
Shares used in computing basic net loss per share	111,856,473	111,856,473
Shares used in computing diluted net loss per share	111,856,473	111,856,473
Product [Member]
Total revenue	$ 555,000	$ 718,000
Royalty [Member]
Total revenue	$ 1,000	$ 4,000

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Balance	$ (2,864,000)	$ 272,000
Share-based compensation expense - stock options	57,000	80,000
Net loss	(689,000)	(735,000)
Balance	(3,496,000)	(383,000)
Common Stock [Member]
Balance	$ 1,119,000	$ 1,119,000
Balance, shares	111,856,473	111,856,473
Share-based compensation expense - stock options
Net loss
Balance	$ 1,119,000	$ 1,119,000
Balance, shares	111,856,473	111,856,473
Additional Paid-in Capital [Member]
Balance	$ 132,612,000	$ 132,398,000
Share-based compensation expense - stock options	57,000	80,000
Net loss
Balance	132,669,000	132,478,000
Retained Earnings [Member]
Balance	(136,595,000)	(133,245,000)
Share-based compensation expense - stock options
Net loss	(689,000)	(735,000)
Balance	$ (137,284,000)	$ (133,980,000)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Operating activities
Net loss	$ (689,000)	$ (735,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	57,000	80,000
Depreciation		37,000
Changes in operating assets and liabilities:
Accounts receivable	(73,000)	(62,000)
Inventories	(16,000)	(16,000)
Prepaid expenses	(20,000)	(39,000)
Accounts payable and accrued liabilities	178,000	274,000
Interest on note payable	60,000	21,000
Net cash used in operating activities	(503,000)	(440,000)
Financing activities
Net proceeds from note payable to related parties	500,000	785,000
Net cash provided by financing activities	500,000	785,000
Net increase (decrease) in cash and cash equivalents, and restricted cash	(3,000)	345,000
Cash and cash equivalents, and restricted cash at beginning of period	424,000	1,170,000
Cash and cash equivalents, and restricted cash at end of period	421,000	1,515,000
Reconciliation of cash and cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	346,000	1,440,000
Restricted cash	75,000	75,000
Total cash and cash equivalents and restricted cash	$ 421,000	$ 1,515,000

Basis of Presentation

Basis of Presentation	3 Months Ended
	Oct. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us,” “its” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary, ETI H20 Inc. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the quarter ended October 31, 2024 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2025. The July 31, 2024 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2024 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 29, 2024. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

Liquidity and Going Concern

Liquidity and Going Concern	3 Months Ended
	Oct. 31, 2024
Liquidity And Going Concern
Liquidity and Going Concern	2. Liquidity and Going Concern The Company has a history of recurring losses, and as of October 31, 2024 it has a stockholders deficiency of $ 3,496,000 689,000 556,000 503,000 346,000 The Company’s future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, its products; the Company’s success and the success of its partners in selling our products; the Company’s success and the success of its partners in obtaining regulatory approvals to sell its products; the costs of further developing the Company’s existing products and technologies; the extent to which the Company invests in new product and technology development; and the costs associated with the continued operation, and any future growth, of its business. The outcome of these and other forward-looking factors will substantially affect its liquidity and capital resources. Until the Company can continually generate positive cash flow from operations, it will need to continue to fund its operations with the proceeds of offerings of our equity and debt securities. However, the Company cannot ensure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or to its stockholders. If the Company raises additional funds from the issuance of equity securities, substantial dilution to its existing stockholders would likely result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict its ability to operate its business.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Oct. 31, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board or the FASB, Accounting Standards Codification or ASC, Topic 606, Revenue from Contracts with Customers or Topic 606. Under Topic 606, revenue is recognized at an amount that reflects the consideration to which it expects to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: 1. Identify the contract with the customer 2. Identify the performance obligations in the contract 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations in the contract 5. Recognize revenue when (or as) each performance obligation is satisfied Under Topic 606, the Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. The Company’s technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers residual protection and formulates well with other compounds. The Company sells various configurations and dilutions of SDC direct to customers and through distributors. The Company currently offers PURE ® ® Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which it considers to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that it satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) it has transferred physical possession of the products, (b) it has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. The Company’s direct customer and distributor sales are invoiced based on received purchase orders. Its payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after it satisfies its performance obligation. The majority of our customers are on 30 day payment terms. The Company currently offers no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. The Company does not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A summary of the Company’s revenue by product type for the fiscal years ended October 31, 2024 and 2023 is as follows: Summary of Revenue by Product 2024 2023 October 31, 2024 2023 PURE Hard Surface $ 389,000 $ 718,000 SILVÉRION 166,000 — Revenue $ 555,000 $ 718,000 Variable Consideration The Company records revenue from customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. From time to time, the Company offer sales promotions on its products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. The Company’s diluted net loss per common share is the same as our basic net loss per common share because it incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of October 31, 2024 and 2023, stock options, shares issuable upon the conversion of debt, and shares issuable under restricted stock unit awards of 37,874,970 and 21,250,985 , respectively, have been excluded from the computation of diluted shares outstanding. Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share 2024 2023 October 31, 2024 2023 Common stock options 10,240,000 8,355,625 Restricted stock units 712,500 712,500 Shares issuable upon the conversion of debt 26,922,470 12,182,860 Total 37,874,970 21,250,985 Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company become aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on our historical losses and an overall assessment of past due trade accounts receivable outstanding. Management determined no allowance for doubtful accounts was necessary at October 31, 2024 and July 31, 2024. Inventory Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Inventories consist of the following: Schedule of Inventories October 31, 2024 July 31, 2024 Raw materials $ 3,000 $ 4,000 Finished goods 69,000 52,000 Inventories $ 72,000 $ 56,000 Inventories at October 31, 2024 and July 31, 2024, are net of a reserve for inventory obsolescence of $ 238,000 Share-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. It accounts for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company estimates the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Concentrations Gross product sales 30 10 10 41 10 Accounts receivable. 45 39 Purchases. 33 18 15 Accounts payable. 16 15 12 Segments The Company operates in one

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Oct. 31, 2024
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	4. Recent Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure, or ASC 280, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment’s profit or loss. The update also requires all annual disclosures about a reportable segment’s profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC 280, including the significant segment expense disclosures. This standard will be effective for the Company beginning in fiscal year 2025. The Company adopted ASU 2023-07 on August 1, 2024, and there was no material impact on its financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Convertible Notes Payable to Re

Convertible Notes Payable to Related Parties	3 Months Ended
	Oct. 31, 2024
Debt Disclosure [Abstract]
Convertible Notes Payable to Related Parties	5. Convertible Notes Payable to Related Parties On September 16, 2024, the Company entered into a Note Purchase Agreement, or the 2025 Note Purchase Agreement, with certain accredited investors, or 2025 Lenders, pursuant to which the Company issued the Lenders convertible promissory notes, or the 2025 Notes, collectively with the 2025 Note Purchase Agreement, the 2025 Note Documents, with an aggregate principal balance of $ 500,000 3.0 Tom Y. Lee, a member of the Company’s Board of Directors, or the Board, invested $ 500,000 500,000 The 2025 Note Documents provided that the interest to the 2025 Lenders shall accrue at the rate of 7.88 Conversion the Company’s common stock is listed or quoted for trading, or the VWAP, on the date of conversion on the last trading day prior to the date of conversion, provided that such conversion price is at least $0.095 per share and less than or equal to $0.175 per share, subject to certain customary adjustments. Additionally, at any time following September 16, 2025, the holders of a majority of the outstanding principal balance under the 2025 Notes may elect specified in writing to convert all of the 2025 Notes at a conversion price equal to the VWAP, provided that the conversion price is equal to at least $0.095 per share, subject to certain customary adjustments. March and June 2024 Convertible Note Purchase Agreements On March 22, 2024, the Company entered into a Note Purchase Agreement, or the 2024 Note Purchase Agreement, with certain accredited investors, or 2024 Lenders, pursuant to which the Company issued the Lenders convertible promissory notes, or the 2024 Notes, collectively with the 2024 Note Purchase Agreement, the 2024 Note Documents, with an aggregate principal balance of $ 500,000 Tom Y. Lee, a member of the Company’s Board, invested $ 500,000 On June 21, 2024, the Company issued an additional 2024 Note to Mr. Lee pursuant to the 2024 Note Purchase Agreement in a subsequent closing with an aggregate principal of $ 500,000 1,000,000 The 2024 Note Documents provided that the interest to the 2024 Lenders shall accrue at the rate of 7.81 Conversion the Company’s common stock is listed or quoted for trading, or the VWAP, on the date of conversion on the last trading day prior to the date of conversion, provided that such conversion price is at least $0.13 per share and less than or equal to $0.21 per share for the March 2024 Note and at least $0.115 per share and less than or equal to $0.195 per share for the June 2024 Note, subject to certain customary adjustments. Additionally, at any time following March 22, 2025, the holders of a majority of the outstanding principal balance under the 2024 Notes may elect specified in writing to convert all of the 2024 Notes at a conversion price equal to the VWAP, provided that the conversion price is equal to at least $0.115 and $0.13 per share, as discussed above, subject to certain customary adjustments. July and October 2023 Convertible Note Purchase Agreements In July, 2023, the Company entered into a Note Purchase Agreement, or the 2023 Note Purchase Agreement with certain accredited investors, or the 2023 Lenders, pursuant to which the Company issued the 2023 Lenders convertible promissory notes, or the 2023 Notes, collectively with the 2023 Note Purchase Agreement, or the 2023 Note Documents, with an aggregate principal balance of $ 1,015,000 1.8 1,000,000 15,000 785,000 1,800,000 The 2023 Note Documents provided that the interest to the Lender shall accrue at the rate of 7.55 7.81 Conversion. the Company’s common stock at a conversion price equal to the VWAP on the date of conversion on the last trading day prior to the date of conversion, provided that such conversion price is at least $0.15 per share and less than or equal to $0.23 per share, subject to certain customary adjustments. Additionally, at any time following July 3, 2024, the holders of a majority of the outstanding principal balance under the 2023 Notes may elect specified in writing to convert all of the Notes at a conversion price equal to the VWAP, provided that the conversion price is equal to at least $0.15 per share, subject to certain customary adjustments. Other terms of the Note Agreements. Further, on all the notes discussed above, in the event of certain corporate transactions, all outstanding principal and unpaid accrued interest due on such Notes shall be automatically converted into conversion shares on the trading day immediately prior to the closing date of such corporate transaction. The number of shares to be issued upon such conversion shall be based on the VWAP on the last trading day prior to the public announcement of the execution of the definitive documents with respect to such transaction. Events of Default Covenants During the three months ended October 31, 2024 and 2023, the Company recognized $ 60,000 21,000 209,000 3,509,000 26,922,470

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Oct. 31, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	6. Share-Based Compensation Restricted Stock Units The Company issues restricted stock unit awards, or RSUs, to key management and as compensation for services to consultants and others. The RSUs typically vest over a one to three-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. The Company determines that fair value of those awards at the date of grant, and amortize those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term. As of October 31, 2024, all the RSUs had vested and 712,500 Stock Option Plans 2024 Equity Incentive Plan The Company’s shareholders approved its 2024 Equity Incentive Plan, or the 2024 Plan, in February 2024, which has a share reserve of 10,000,000 10 7,500,000 During the three months ended October 31, 2024, the Compensation Committee of the Board of Directors granted 2,500,000 148,000 A summary of the Company’s stock option activity is as follows: Schedule of Stock Option Activity Shares Weighted- Aggregate Outstanding at July 31, 2024 7,740,000 0.40 $ — Granted 2,500,000 0.07 60,000 Exercised — — — Cancelled — — — Outstanding at October 31, 2024 10,240,000 0.32 $ 60,000 The weighted-average remaining contractual term of options outstanding at October 31, 2024 was 7.45 At October 31, 2024, options to purchase 7,954,167 0.39 6.81 101,000 0.78 For the three months ended October 31, 2024, share-based compensation expense for stock options that vested during the period was $ 57,000 80,000 We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions: Schedule of Fair Value Assumptions For the three months ended October 31, 2024 2023 Volatility 118.49 % 110.95 % Risk-free interest rate 3.86 % 4.18 % Dividend yield — % — % Expected life 5.26 5.36 Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation. The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Oct. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions As of October 31, 2024 and October 31, 2023, accounts payable include $ 185,700 135,300

Subsequent Events

Subsequent Events	3 Months Ended
	Oct. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events Note with Related Parties On December 5, 2024, the Company issued an additional Note to Mr. Lee pursuant to the 2025 Note Purchase Agreement in a subsequent closing with an aggregate principal of $ 150,000

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Oct. 31, 2024
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board or the FASB, Accounting Standards Codification or ASC, Topic 606, Revenue from Contracts with Customers or Topic 606. Under Topic 606, revenue is recognized at an amount that reflects the consideration to which it expects to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: 1. Identify the contract with the customer 2. Identify the performance obligations in the contract 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations in the contract 5. Recognize revenue when (or as) each performance obligation is satisfied Under Topic 606, the Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those goods or services. The Company’s technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers residual protection and formulates well with other compounds. The Company sells various configurations and dilutions of SDC direct to customers and through distributors. The Company currently offers PURE ® ® Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which it considers to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that it satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) it has transferred physical possession of the products, (b) it has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. The Company’s direct customer and distributor sales are invoiced based on received purchase orders. Its payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after it satisfies its performance obligation. The majority of our customers are on 30 day payment terms. The Company currently offers no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. The Company does not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A summary of the Company’s revenue by product type for the fiscal years ended October 31, 2024 and 2023 is as follows: Summary of Revenue by Product 2024 2023 October 31, 2024 2023 PURE Hard Surface $ 389,000 $ 718,000 SILVÉRION 166,000 — Revenue $ 555,000 $ 718,000 Variable Consideration The Company records revenue from customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. From time to time, the Company offer sales promotions on its products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.
Net Loss Per Share	Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. The Company’s diluted net loss per common share is the same as our basic net loss per common share because it incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of October 31, 2024 and 2023, stock options, shares issuable upon the conversion of debt, and shares issuable under restricted stock unit awards of 37,874,970 and 21,250,985 , respectively, have been excluded from the computation of diluted shares outstanding. Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share 2024 2023 October 31, 2024 2023 Common stock options 10,240,000 8,355,625 Restricted stock units 712,500 712,500 Shares issuable upon the conversion of debt 26,922,470 12,182,860 Total 37,874,970 21,250,985
Accounts Receivable	Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company become aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on our historical losses and an overall assessment of past due trade accounts receivable outstanding. Management determined no allowance for doubtful accounts was necessary at October 31, 2024 and July 31, 2024.
Inventory	Inventory Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Inventories consist of the following: Schedule of Inventories October 31, 2024 July 31, 2024 Raw materials $ 3,000 $ 4,000 Finished goods 69,000 52,000 Inventories $ 72,000 $ 56,000 Inventories at October 31, 2024 and July 31, 2024, are net of a reserve for inventory obsolescence of $ 238,000
Share-Based Compensation	Share-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. It accounts for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company estimates the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures.
Concentrations	Concentrations Gross product sales 30 10 10 41 10 Accounts receivable. 45 39 Purchases. 33 18 15 Accounts payable. 16 15 12
Segments	Segments The Company operates in one

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	3 Months Ended
	Oct. 31, 2024
Accounting Policies [Abstract]
Summary of Revenue by Product	A summary of the Company’s revenue by product type for the fiscal years ended October 31, 2024 and 2023 is as follows: Summary of Revenue by Product 2024 2023 October 31, 2024 2023 PURE Hard Surface $ 389,000 $ 718,000 SILVÉRION 166,000 — Revenue $ 555,000 $ 718,000
Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share	Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share 2024 2023 October 31, 2024 2023 Common stock options 10,240,000 8,355,625 Restricted stock units 712,500 712,500 Shares issuable upon the conversion of debt 26,922,470 12,182,860 Total 37,874,970 21,250,985
Schedule of Inventories	Inventories consist of the following: Schedule of Inventories October 31, 2024 July 31, 2024 Raw materials $ 3,000 $ 4,000 Finished goods 69,000 52,000 Inventories $ 72,000 $ 56,000

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Oct. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of the Company’s stock option activity is as follows: Schedule of Stock Option Activity Shares Weighted- Aggregate Outstanding at July 31, 2024 7,740,000 0.40 $ — Granted 2,500,000 0.07 60,000 Exercised — — — Cancelled — — — Outstanding at October 31, 2024 10,240,000 0.32 $ 60,000
Schedule of Fair Value Assumptions	Schedule of Fair Value Assumptions For the three months ended October 31, 2024 2023 Volatility 118.49 % 110.95 % Risk-free interest rate 3.86 % 4.18 % Dividend yield — % — % Expected life 5.26 5.36

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Liquidity And Going Concern
Stockholders deficiency	$ 3,496,000	$ 383,000	$ 2,864,000	$ (272,000)
Net loss	689,000	735,000
Revenue	556,000	722,000
Net cash provided by (used) in operating activities	503,000	440,000
Cash and cash equivalents	$ 346,000	$ 1,440,000	$ 349,000

Summary of Revenue by Product (

Summary of Revenue by Product (Details) - USD ($)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Product Information [Line Items]
Revenue	$ 555,000	$ 718,000
PURE Hard Surface [Member]
Product Information [Line Items]
Revenue	389,000	718,000
SIL VERION [Member]
Product Information [Line Items]
Revenue	$ 166,000

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share (Details) - shares	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	37,874,970	21,250,985
Common Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	10,240,000	8,355,625
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	712,500	712,500
Shares Issuable Upon Conversion of Debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	26,922,470	12,182,860

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($)	Oct. 31, 2024	Jul. 31, 2024
Accounting Policies [Abstract]
Raw materials	$ 3,000	$ 4,000
Finished goods	69,000	52,000
Inventories	$ 72,000	$ 56,000

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative)	3 Months Ended
	Oct. 31, 2024 USD ($) Segments shares	Oct. 31, 2023 shares	Jul. 31, 2024 USD ($)
Product Information [Line Items]
Antidilutive securities | shares	37,874,970	21,250,985
Inventory, reserve | $	$ 238,000		$ 238,000
Number of operating segments | Segments	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Individual Customer One [Member]
Product Information [Line Items]
Concentration risk percentage	30%	41%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Individual Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage	10%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Individual Customer [Member]
Product Information [Line Items]
Concentration risk percentage	10%	10%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk percentage	45%	39%
Customer Concentration Risk [Member] | Purchases [Member] | Vendor One [Member]
Product Information [Line Items]
Concentration risk percentage	33%	18%
Customer Concentration Risk [Member] | Purchases [Member] | Vendor Two [Member]
Product Information [Line Items]
Concentration risk percentage		15%
Customer Concentration Risk [Member] | Accounts Payable [Member] | Vendor One [Member]
Product Information [Line Items]
Concentration risk threshold percentage	16%	15%
Customer Concentration Risk [Member] | Accounts Payable [Member] | Vendor Two [Member]
Product Information [Line Items]
Concentration risk threshold percentage		12%

Convertible Notes Payable to _2

Convertible Notes Payable to Related Parties (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended
	Sep. 16, 2024	Jun. 21, 2024	Jul. 31, 2023	Oct. 31, 2024	Oct. 31, 2023	Mar. 22, 2024	Oct. 20, 2023
Short-Term Debt [Line Items]
Conversion price, description		the Company’s common stock is listed or quoted for trading, or the VWAP, on the date of conversion on the last trading day prior to the date of conversion, provided that such conversion price is at least $0.13 per share and less than or equal to $0.21 per share for the March 2024 Note and at least $0.115 per share and less than or equal to $0.195 per share for the June 2024 Note, subject to certain customary adjustments. Additionally, at any time following March 22, 2025, the holders of a majority of the outstanding principal balance under the 2024 Notes may elect specified in writing to convert all of the 2024 Notes at a conversion price equal to the VWAP, provided that the conversion price is equal to at least $0.115 and $0.13 per share, as discussed above, subject to certain customary adjustments.	the Company’s common stock at a conversion price equal to the VWAP on the date of conversion on the last trading day prior to the date of conversion, provided that such conversion price is at least $0.15 per share and less than or equal to $0.23 per share, subject to certain customary adjustments. Additionally, at any time following July 3, 2024, the holders of a majority of the outstanding principal balance under the 2023 Notes may elect specified in writing to convert all of the Notes at a conversion price equal to the VWAP, provided that the conversion price is equal to at least $0.15 per share, subject to certain customary adjustments.
Interest on note payable				$ 60,000	$ 21,000
Interest payable				209,000
Notes payable				$ 3,509,000
Common Stock [Member]
Short-Term Debt [Line Items]
Notes and accrued interest convered into common stock				26,922,470
Private Placement [Member] | Tom Y. Lee [Member] | 2023 Note Purchase Agreement [Member]
Short-Term Debt [Line Items]
Investments amount			$ 1,000,000
Private Placement [Member] | Ivan Chen [Member] | 2023 Note Purchase Agreement [Member]
Short-Term Debt [Line Items]
Investments amount			15,000
2025 Note Purchase Agreement [Member]
Short-Term Debt [Line Items]
Aggregate principal balance	$ 500,000			$ 500,000
Aggregate offering	$ 3,000,000
Interest rate	7.88%
Conversion price, description	the Company’s common stock is listed or quoted for trading, or the VWAP, on the date of conversion on the last trading day prior to the date of conversion, provided that such conversion price is at least $0.095 per share and less than or equal to $0.175 per share, subject to certain customary adjustments. Additionally, at any time following September 16, 2025, the holders of a majority of the outstanding principal balance under the 2025 Notes may elect specified in writing to convert all of the 2025 Notes at a conversion price equal to the VWAP, provided that the conversion price is equal to at least $0.095 per share, subject to certain customary adjustments.
2025 Note Purchase Agreement [Member] | Private Placement [Member] | Tom Y. Lee [Member]
Short-Term Debt [Line Items]
Investments amount	$ 500,000
March 2024 Convertible Note Purchase Agreements [Member]
Short-Term Debt [Line Items]
Aggregate principal balance						$ 500,000
March 2024 Convertible Note Purchase Agreements [Member] | Tom Y. Lee [Member]
Short-Term Debt [Line Items]
Investments amount						$ 500,000
July 2024 Convertible Note Purchase Agreements [Member]
Short-Term Debt [Line Items]
Aggregate principal balance		$ 500,000		1,000,000
June 2024 Note Purchase Agreement [Member]
Short-Term Debt [Line Items]
Interest rate		7.81%
July and October 2023 Convertible Note Purchase Agreements [Member] | 2023 Note Purchase Agreement [Member]
Short-Term Debt [Line Items]
Aggregate principal balance			1,015,000	$ 1,800,000
Aggregate offering			$ 1,800,000
July and October 2023 Convertible Note Purchase Agreements [Member] | Mr.Lee [Member] | 2023 Note Purchase Agreement [Member]
Short-Term Debt [Line Items]
Aggregate principal balance							$ 785,000
July 2023 Note Purchase Agreement [Member] | 2023 Notes [Member]
Short-Term Debt [Line Items]
Interest rate			7.55%
October 2023 Note Purchase Agreement [Member] | 2023 Notes [Member]
Short-Term Debt [Line Items]
Interest rate			7.81%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - 2024 Equity Incentive Plan [Member]	3 Months Ended
	Oct. 31, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options Outstanding Shares, Beginning Balance | shares	7,740,000
Weighted- Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 0.40
Aggregate Intrinsic Value Outstanding, Beginning Balance | $
Shares, Granted | shares	2,500,000
Weighted- Average Exercise Price, Granted | $ / shares	$ 0.07
Aggregate Intrinsic Value, Granted | $	$ 60,000
Shares, Exercised | shares
Weighted- Average Exercise Price, Exercised | $ / shares
Shares, Cancelled | shares
Weighted- Average Exercise Price, Cancelled | $ / shares
Options Outstanding Shares, Ending Balance | shares	10,240,000
Weighted- Average Exercise Price Outstanding, Ending Balance | $ / shares	$ 0.32
Aggregate Intrinsic Value Outstanding, Ending Balance | $	$ 60,000

Schedule of Fair Value Assumpti

Schedule of Fair Value Assumptions (Details)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Share-Based Payment Arrangement [Abstract]
Volatility	118.49%	110.95%
Risk-free interest rate	3.86%	4.18%
Dividend yield
Expected life	5 years 3 months 3 days	5 years 4 months 9 days

Share-Based Compensation (Detai

Share-Based Compensation (Details Narrative) - USD ($)		3 Months Ended
	Feb. 29, 2024	Oct. 31, 2024	Oct. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options issued to purchase common stock exercisable		7,954,167
Weighted average exercise price		$ 0.39
Weighted average contractual term		6 years 9 months 21 days
Unrecognized non-cash compensation costs		$ 101,000
Unrecognized non-cash compensation costs for weighted average contractual term grants		9 months 10 days
Share-based compensation		$ 57,000	$ 80,000
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average contractual term		7 years 5 months 12 days
Employees Officers Directors and Consultants [Member] | Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted shares		2,500,000
Options, vested in period, fair value		$ 148,000
2024 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock shares	10,000,000
Share-based compensation, vesting period	10 years
Number of shares available for issuance under the plan		7,500,000
Restricted Stock Units (RSUs) [Member] | Vested and Issuable [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of units, vested and issuable		712,500

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Oct. 31, 2024	Jul. 31, 2024	Oct. 31, 2023
Accounts payable	$ 718,000	$ 601,000
Board Fees due to Officers and Directors [Member]
Accounts payable	$ 185,700		$ 135,300

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - 2025 Note Purchase Agreement [Member] - USD ($)	Dec. 05, 2024	Oct. 31, 2024	Sep. 16, 2024
Subsequent Event [Line Items]
Aggregate principal balance		$ 500,000	$ 500,000
Mr.Lee [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate principal balance	$ 150,000